Hydroxymethylglutaryl-CoA Reductase Inhibitors

Goccioline del contagio e mascherine FANS e polmonite: più no che sì Abbasso il colesterolo: ma come? Kawasaki… a tappe Terapia dell’emangioma infantile. Una significativa controprova Repetita juvant?

2020/4 — pag. 213-214

Abbasso il colesterolo (da subito) Per Regio Decreto Aggiunta di latte al Nido? No grazie Il valore del marsupio Alopecia areata Tracce di... niente Suscettibilità al morbillo del neonato Auguri e promemoria dalla Gialla

2020/1 — pag. 9-10

La gestione del bambino con ipercolesterolemia familiare

G.G. Viviano

2014/2

Among hypercholesterolaemias, familial hypercholesterolaemia is a hereditary dyslipidaemia characterised by an isolated and permanent increase in circulating low-density lipoprotein (LDL) levels. The heterozygous form is often clinically silent and m...

L'uso dei farmaci in Italia: i risultati del rapporto OsMed 2008

F. Marchetti

2009/7 — pag. 450-454

The data relative to the OsMed report on the drug prescription in Italy during 2008 are summed up in the present work. The total cost for drugs (public + private) was equal to 410 euros for each citizen, 24 billion euros, a much higher sum than the...

Le statine per i bambini? Poche luci, molte ombre

F. Marchetti, Z. Cannioto

2008/7 — pag. 415-417

Statine, iperlipidemia e obesità. Stato dell’arte

Zemira Cannioto

2008/5 — pag. 309-318

The prevalence of lipid abnormalities in children is increasing in relation to the concomitant epidemic of obesity and metabolic syndrome. The 3-hydroxy-3-metylglutaryl coenzyme A reductase inhibitor and statins have been shown to effectively reduce ...

Le statine in età pediatrica

Z. Cannioto

2007/8